Showing 2811-2820 of 3223 results for "".
- Pfizer CEO Says Late November is Earliest Possible Filing Date for COVID-19 Vaccine in UShttps://modernod.com/news/pfizer-ceo-says-late-november-is-earliest-possible-filing-date-for-covid-19-vaccine-in-us/2478428/Pfizer CEO Albert Bourla said that the earliest the company will apply for FDA emergency-use authorization (EUA) for its COVID-19 vaccine program would be shortly after a key safety milestone is met, which is currently expected to be in the third week of November. “As we get closer to an im
- Study of Lilly’s COVID-19 Antibody LY-CoV555 Paused Over Potential Safety Issuehttps://modernod.com/news/study-of-lillys-covid-19-antibody-ly-cov555-paused-over-potential-safety-issue/2478416/A phase 3 trial of Eli Lilly’s investigational monoclonal antibody LY-CoV555 for the treatment of COVID-19 has been temporarily suspended out of an “abundance of caution” because of a “potential safety concern,” according to emails that government officials sent on T
- Hoya Surgical Optics Announces Global Launch of CLEARlog Apphttps://modernod.com/news/hoya-surgical-optics-announces-global-launch-of-clearlog-app/2478409/During the virtual ESCRS, the CLEARlog app was launched with the support of Hoya Surgical Optics. CLEARlog, which stands for “Cataract & Lens Exchange Analysis & Register” log, is an app that allows Cataract and Refractive Lens Exchange (RLE) surgeons to quickly and eff
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- Lilly, Incyte’s Olumiant Shows “Significant Effect” on COVID-19 Recovery Timeshttps://modernod.com/news/lilly-incytes-olumiant-shows-significant-effect-on-covid-19-recovery-times/2478401/Eli Lilly and Incyte shared more details, including mortality data, from the ongoing ACTT 2 trial evaluating their JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) in patients with COVID-19 infection. The companies said last month that the
- Oertli Releases Two Trocar Based Chandelier Solutionshttps://modernod.com/news/oertli-releases-two-trocar-based-chandelier-solutions/2478389/Oertli announced the release of two trocar based chandelier solutions. Using chandelier illumination provides a true bimanual manipulation during vitreoretinal surgery and also one-step access for an easy and quick connection. Chandelier illumination is beneficial for improving intraocular
- Johnson & Johnson Vision Presents New Myopia Progression and Contact Lens Findings at American Academy of Optometry Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-presents-new-myopia-progression-and-contact-lens-findings-at-american-academy-of-optometry-annual-meeting/2478387/Johnson & Johnson Vision announced clinical data from the latest in myopia research at the American Academy of Optometry’s virtual annual meeting (Academy 2020). Investigators will also reveal findings that demonstrate how Acuvue Oasys 1-Day with Hydraluxe Technology Contact Lenses redu
- Beovu Now Available in Canada, Receives Positive Reimbursement Recommendationhttps://modernod.com/news/beovu-now-available-in-canada-receives-positive-reimbursement-recommendation/2478363/Novartis Pharmaceuticals Canada has announced that Beovu (brolucizumab injection) is now available in Canada for the treatment of wet age-related macular degeneration (AMD). The anti-VEGF therapy for wet AMD offers the option for eligible patients to start on 3-mo
- Centricity Vision Appoints Jim Mazzo to its Board of Directorshttps://modernod.com/news/centricity-vision-appoints-jim-mazzo-to-its-board-of-directors/2478353/Centricity Vision announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mr. Mazzo has over 40 years of experience in the ophthalmology industry. His global reputation for building and running world-class organizations is based on 22 years leading Allergan’s North
- Moderna’s mRNA-1273 COVID-19 Vaccine Generates Immune Responses in Older Adultshttps://modernod.com/news/modernas-mrna-1273-covid-19-vaccine-generates-immune-responses-in-older-adults/2478351/Moderna said data published in the NEJM showed that its mRNA-1273 vaccine candidate against COVID-19 was well tolerated and generated strong immune responses in older adults. “These interim phase 1 data suggest that mRNA-1273 … can generate neutralizing antibodies in older and elderly adult